CytomX Therapeutics, Inc. reported $18M of revenue over the trailing twelve months, −87% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $18M (to Q2 2026). Net income: −$80M, trailing twelve months to Q2 2026. Free cash flow: −$83M, trailing twelve months to Q2 2026. Operating margin: −1587%, trailing twelve months to Q2 2026.

CTMXCytomX Therapeutics, Inc.

Healthcare

$2.46-26% 1Y

$2.46

$2.4652 weeks$6.75

Latest close: a new 52-week lowOct 8, 2026what changed →

CTMX as reported

CytomX Therapeutics, Inc. reported $18M of revenue over the trailing twelve months, −87% on the year before. 8 reported series are charted on this page, each one as filed.

$18M

Revenue, trailing twelve months · to Q2 2026 · −87% against the twelve months before

Net income: −$80M
Net income · −266% year on year · trailing twelve months to Q2 2026
Free cash flow: −$83M
Free cash flow · +6.5% year on year · trailing twelve months to Q2 2026
Operating margin: −1587%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CTMX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$18M	−87%	Q2 2026
Net income	−$80M	−266%	Q2 2026
EPS	−$0.50	−188%	Q2 2026
Operating margin	−1587%	n/a	Q2 2026
Net margin	−1468%	n/a	Q2 2026
ROE	−9.1%	n/a	Q2 2026
ROA	−7.8%	n/a	Q2 2026
Free cash flow	−$83M	+6.5%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.